AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15457551
Drug: IFN-alpha2b +
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha2b + ribavirin (treatment group = TG)
Trial: 15457551
Drug: Old treatment
RxNorm normalized name: GLYCERIN 0.01 g in 1 mL TOPICAL LIQUID [BURZANGMURY GOLD TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Old treatment control group (OTCG) with IFN-alpha2b
Trial: 29565472
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) with no treatment
Trial: 11466162
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract (EGb) administered for 30 days
Trial: 7697239
Drug: TOPA (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TOPA (10% lidocaine spray and 0.25% bupivocaine gargle)
Trial: 2689014
Drug: Terbinafine 125
RxNorm normalized name: terbinafine 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 125 mg b.i.d.
Trial: 2689014
Drug: Griseofulvin 250
RxNorm normalized name: griseofulvin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Griseofulvin 250 mg (microsize) b.i.d.
Trial: 22892141
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behaviour therapy (CBT) after psycho-education materials
Trial: 21493672
Drug: Oxandrolone (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone (0.05 mg/kg/day, maximum 2.5 mg/day)
Trial: 19621690
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g AzOAB: Azithromycin 500 mg twice daily for 3 days and Omeprazole 20 mg, Amoxicillin 1 g, Bismuth 240 mg all twice daily for 1 week
Trial: 8279244
Drug: Alfentanil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 20 micrograms.kg‐1 + lidocaine 1 mg.kg‐1
Trial: 26147383
Drug: B-vitamin supplementation
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin supplementation (500 μg vitamin B12 and 400 μg folic acid)
Trial: 19912283
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem (DTZ) ointment (2%; n = 16)
Trial: 2909831
Drug: Aspartame (APM)
RxNorm normalized name: Aspartame
DrugBank: Aspartame (DB00168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (APM) at 10 mg APM/kg body weight per serving, ingested in three successive 12-oz servings at 2-hour intervals (study 1)
Trial: 2645561
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 50 mg (q.i.d.)
Trial: 2645561
Drug: Nefopam 60
RxNorm normalized name: nefopam 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 60 mg (q.i.d.)
Trial: 2645561
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 640 mg + codeine 40 mg (q.i.d.)
Trial: 31325020
Drug: Positional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positional therapy (PT)
Trial: 23039931
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS treatment (n = 13)
Trial: 23039931
Drug: Sham rTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rTMS treatment (n = 12)
Trial: 28863074
Drug: Pro-CHO (CHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro-CHO (CHO (15 g) + whey protein (10 g))
Trial: 18719788
Drug: Dexmedetomidine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine group (n=13): infusion of 1 microg/kg over 10 minutes and maintenance dose of 0.5 microg/kg/h as an adjuvant to inhaled isoflurane anesthesia
Trial: 18719788
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=13): normal saline infusion at a similar rate and volume of the dexmedetomidine infusion
Trial: 17027362
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg mifepristone (group I)
Trial: 20684146
Drug: 15% azelaic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% azelaic acid gel
Trial: 11078311
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (900 calories, 50 g of fat)
Trial: 11078311
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (900 calories, 4 g of fat)
Trial: 30420421
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor or ARB monotherapy or combination therapy
Trial: 27593617
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (140 ml daily, containing approximately 10 mmol of nitrate)
Trial: 22081005
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg/day)
Trial: 22193531
Drug: Fluoxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10 mg/day to 80 mg/day over 12 weeks)
Trial: 18197096
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg/dose
Trial: 8137520
Drug: Sumatriptan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (6 mg, subcutaneous injection)
Trial: 2573377
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tertatolol (T)
Trial: 2573377
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg atenolol (A)
Trial: 1053694
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality therapy (chemotherapy and irradiation)
Trial: 22428494
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg of ketamine (Group K2)
Trial: 17143189
Drug: mibefradil 100
RxNorm normalized name: mibefradil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mibefradil 100 mg daily
Trial: 17143189
Drug: amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine 10 mg daily
Trial: 15334195
Drug: Sirolimus (SRL)
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus (SRL) 2 mg/day, po with CsA (8-10 mg/kg/day, po) and prednisone (0.5 mg/day, po)
Trial: 2506754
Drug: Rilmenidine 1
RxNorm normalized name: rilmenidine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmenidine 1 mg and 2 mg
Trial: 1098875
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg on the first day followed by 100 mg daily for a total of 7 days)
Trial: 1098875
Drug: Ampicillin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (250 mg 4 times daily for 7 days)
Trial: 17722826
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with the same methods as the treatment group but without acupuncture at the acute stage.
Trial: 7855937
Drug: Conventional digital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional digital rectal examination (DRE)
Trial: 10431942
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of caffeine
Trial: 3602266
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 mg)
Trial: 770365
Drug: nialamide +
RxNorm normalized name: nialamide
DrugBank: Nialamide (DB04820)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nialamide + l-5-HTP
Trial: 26541963
Drug: Mentor Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentor Support by mentors with a visual impairment in combination with care-as-usual
Trial: 26541963
Drug: Mentor Support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentor Support by mentors without visual impairments in combination with care-as-usual
Trial: 9152683
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d beta-carotene and placebo for alpha-tocopherol
Trial: 25187667
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg/day) from day 5 to day 7
Trial: 22208477
Drug: Liu Wei
RxNorm normalized name: Bai Liu Bark
DrugBank: Salix alba bark (DB14274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liu Wei Di Huang Wan (LDW) 4.8 g (12 pills, 0.2 g/pill, twice daily) for 14 days
Trial: 20660002
Drug: Radioiodine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine treatment
Trial: 26637849
Drug: Oral progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral progestin (10 mg medroxyprogesterone acetate (MPA) taken continuously)
Trial: 19178095
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (InT) performed within 24 hours
Trial: 19178095
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (CoT) with one treatment session a week for 4 weeks
Trial: 453892
Drug: SEUV TG
RxNorm normalized name: TG-1042
DrugBank: TG-1042 (DB18435)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEUV TG (suberythemogenic ultraviolet phototherapy with tar gel)
Trial: 453892
Drug: Modified Goeckerman
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Goeckerman (erythemogenic tar gel phototherapy regimen)
Trial: 453892
Drug: Tar gel
RxNorm normalized name: Betatar Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tar gel alone
Trial: 453892
Drug: SEUV irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SEUV irradiation following application of gel vehicle
Trial: 24983350
Drug: MVG 1.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVG 1.3% once daily for 3 days
Trial: 24983350
Drug: MVG 1.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVG 1.3% once daily for 5 days
Trial: 24983350
Drug: MVG 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVG 0.75% once daily for 5 days
Trial: 12928870
Drug: Imidacloprid 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidacloprid 10% w/v / Permethrin 50% w/v combination
Trial: 10945514
Drug: Combination hydrocodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination hydrocodone 7.5 mg and ibuprofen 200 mg (2-tablet dose)
Trial: 8495454
Drug: Domperidone 30
RxNorm normalized name: domperidone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 30 mg plus paracetamol 1 g
Trial: 8495454
Drug: Paracetamol 1
RxNorm normalized name: Paracetamol 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1 g alone
Trial: 30290667
Drug: Desflurane inhalation
RxNorm normalized name: Desflurane Inhalation Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desflurane inhalation anesthesia
Trial: 27758944
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg once daily for 90 days
Trial: 27758944
Drug: Simvastatin treatment
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin treatment in patients receiving tissue‐type plasminogen activator
Trial: 23494629
Drug: 300‐U onabotulinumtoxinA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300‐U onabotulinumtoxinA injections
Trial: 12928982
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg daily) after a montelukast-free period of one day
Trial: 12928982
Drug: Montelukast (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (10 mg daily) after a montelukast-free period of three days
Trial: 10026401
Drug: Kerasal 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kerasal 5% ointment
Trial: 9620898
Drug: HR3 (rifampin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR3 (rifampin plus isoniazid, 3 times weekly)
Trial: 9620898
Drug: HRp1 (rifapentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRp1 (rifapentine plus isoniazid, once weekly)
Trial: 22992296
Drug: Combination NRT
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination NRT for 2 weeks
Trial: 22992296
Drug: 2-week combination
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2-week combination NRT
Trial: 22992296
Drug: 6-week combination
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week combination NRT
Trial: 21256048
Drug: Tadalafil 40
RxNorm normalized name: tadalafil 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 40 mg
Trial: 3569063
Drug: Ismo 20
RxNorm normalized name: Ismo 20mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ismo 20 (40 mg IS-5-N daily)
Trial: 3569063
Drug: Corangin 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corangin 20 (40 mg IS-5-N daily)
Trial: 3569063
Drug: Corangin 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corangin 40 (40 mg IS-5-N once a day)
Trial: 3569063
Drug: Corangin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corangin 60 (60 mg IS-5-N once a day)
Trial: 3569063
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release preparations (Corangin 40 and Corangin 60)
Trial: 24886681
Drug: Granulocyte colony‐stimulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony‐stimulating factor (G‐CSF) for 5 days followed by autologous MSCs peripheral‐vein infusion
Trial: 22225697
Drug: GPM +
RxNorm normalized name: PHENYLADE GPM ULTRA POWDER PACKET,33.4GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GPM + DBT‐M treatment
Trial: 20041478
Drug: Psychosocial interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychosocial interventions targeting medication adherence as a secondary outcome
Trial: 16364056
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole orally for 2 days b.i.d.
Trial: 10447055
Drug: Liquid cooling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid cooling (L)
Trial: 28696373
Drug: Weekly upper
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly upper limb rehabilitation for 24 weeks
Trial: 21724070
Drug: 8% hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% hydrogen peroxide bleaching agent after orthodontic treatment (group B)
Trial: 16739368
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg omeprazole MUPS
Trial: 31096515
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg esomeprazole
Trial: 8687090
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by thymosin alpha1 + low-dose IFNalpha
Trial: 8687090
Drug: Chemotherapy (ifosfamide)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (ifosfamide)
Trial: 25715364
Drug: HIFU combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU combined with chemotherapy (group B)
Trial: 1532198
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (group A)
Trial: 19041284
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of sustained-release isradipine
Trial: 15051743
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium (500 mg bid)
Trial: 15888797
Drug: PEG‐IFN‐alpha‐2b (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐alpha‐2b (1.5 mug/kg) once weekly plus daily ribavirin (1000‐1200 mg) for 48 weeks
Trial: 7638969
Drug: Isosorbide-5-mononitrate (IS-5-MN)
RxNorm normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide-5-mononitrate (IS-5-MN) 60 mg once daily
Trial: 19994687
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Valaciclovir Hydrochlordide, Indomethacin, Vitamin B1 and Vitamin B12
Trial: 16962390
Drug: Tropisetron preparation
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron preparation 1
Trial: 7894213
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nifedipine GITS administered at 1000 hours
Trial: 7894213
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nifedipine GITS administered at 2200 hours
Trial: 26677212
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1.0 g/d)
Trial: 12354713
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide with oxygen
Trial: 766252
Drug: Intrathoracic BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathoracic BCG (single dose)
Trial: 30980514
Drug: golimumab 2
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: golimumab 2 mg/kg at weeks 0, 4, and every 8 weeks thereafter
Trial: 30980514
Drug: golimumab 2
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: golimumab 2 mg/kg
Trial: 19639067
Drug: Two-implant group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-implant group
Trial: 19639067
Drug: Single-implant group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-implant group
Trial: 3470961
Drug: PGE1 treatment
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 treatment group
Trial: 3286673
Drug: Pulsatile insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulsatile insulin delivery (5.2 mU kg‐1 min‐1, 2/11 min on/off)
Trial: 3286673
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin delivery (0.8 mU kg‐1 min‐1 for normal men; 0.15 mU kg‐1 min‐1 for type 1 diabetic patients)
Trial: 3286673
Drug: Intermittent insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent insulin delivery (0.97 mU kg‐1 min‐1 for 2 min, followed by 11 min no infusion for type 1 diabetic patients)
Trial: 23642377
Drug: Bevacizumab (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (monthly or as-needed)
Trial: 19309712
Drug: Primary PCI
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary PCI with triple antiplatelet therapy
Trial: 16681559
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin inhalation powder (HIIP)
Trial: 16681559
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) insulin
Trial: 9430375
Drug: Simvastatin 160
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin 160 mg/day (group 1)
Trial: 3307620
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate lozenges (10 mg), average utilization 5.4 days at an average dose of six lozenges daily
Trial: 3307620
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate lozenges (10 mg)
Trial: 23295793
Drug: Toremifene citrate
RxNorm normalized name: Toremifene Citrate
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toremifene citrate 20 mg
Trial: 21426748
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy group (50 patients)
Trial: 21426748
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy group (50 patients) with MLA < 4.0 mm(2)
Trial: 17962712
Drug: Echinacea (ECH)
RxNorm normalized name: Echinacea
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinacea (ECH) 8000 mg/d (5 x 400 mg x 4 times/d for 28 days)